Recent Updates
Recently added Catalysts

Dexmedetomidine

Phase 1

Alzheimer Disease | Small molecule | Neurology |Cognition Therapeutics, Inc.|Last Updated: Feb 25, 2026

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
Double-BlindPLACEBO_CONTROLLEDBiomarker
Total Trials1
Total Enrollment31
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT07432997Pharmacological Enhancement of Glymphatic Function in HumansPHASE1 COMPLETED 31 — — Dec 11, 2023Sep 13, 2024Feb 25, 20262 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Mean change from baseline in plasma Aβ42/Aβ40 ratio following dexmedetomidine treatment
Pre/post 4-hour sleep period

Measured with mass spectrometry

Mean change from baseline in plasma Aβ42/Aβ40 ratio following dexmedetomidine and midodrine treatment
Pre/post 4-hour sleep period

Measured with mass spectrometry

Mean change from baseline in plasma %p-tau217 following dexmedetomidine treatment
Pre/post 4-hour sleep period

Measured with mass spectroscopy

Mean change from baseline in plasma %p-tau217 following dexmedetomidine and midodrine treatment
Pre/post 4-hour sleep period

Measured with mass spectroscopy

Unlock Study Endpoints
Study Design & Arms
AllocationNON_RANDOMIZED
MaskingDOUBLE
ModelCROSSOVER
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Dexmedetomidine Cross-Over PlaceboPLACEBO_COMPARATOR -
Dexmedetomidine Cross-Over TreatmentACTIVE_COMPARATOR -
Dexmedetomidine & Midodrine Cross-Over TreatmentACTIVE_COMPARATOR -
Dexmedetomidine & Midodrine Cross-Over PlaceboPLACEBO_COMPARATOR -
Interventions
NameTypeDescription
DexmedetomidineDRUGTreatment
Dexmedetomidine and MidodrineDRUGTreatment
PlaceboOTHERPlacebo
Unlock Study Design Details
Eligibility Criteria
Age Range55 Years — 65 Years
SexALL
Healthy VolunteersYes
Study Sites2

Inclusion Criteria: Potential participants must satisfy the following criteria to be enrolled in the study: 1. In the opinion of the Principal Investigator, participants must be fluent in English and be able to understand the informed consent form approved by the Institutional Review Board (IRB). ...

Countries:United States
Unlock Eligibility Criteria
Competitive Landscape -Alzheimer's Disease 68 trials
CompanyTickerTrialsLead PhaseDrugs
Bristol-Myers Squibb CompanyBMY9PHASE3KarXT, KarX-EC, Xanomeline/Trospium Chloride, Xanomeline Enteric, BMS-986446
Eli Lilly and CompanyLLY13PHASE3Donanemab, Dexamethasone, Remternetug, Mevidalen, LY3954068
Biogen Inc.BIIB2PHASE3Lecanemab
Annovis Bio IncANVS1PHASE3buntanetap/posiphen
ACADIA Pharmaceuticals Inc.ACAD2PHASE3ACP-204
Novartis AG Sponsored ADRNVS2PHASE2VHB937, NIO752
Merck & Co., Inc.MRK2PHASE2MK-1167, MK-2214
GSK plc Sponsored ADRGSK2PHASE2GSK4527226
Cognition Therapeutics, Inc.CGTX2PHASE2CT1812
Johnson & JohnsonJNJ1PHASE2JNJ-64042056
Acumen Pharmaceuticals, Inc.ABOS1PHASE2sabirnetug
Lantheus Holdings IncLNTH2PHASE3Nilotinib BE, PI-2620
Aclaris Therapeutics, Inc.ACRS1PHASE2ATI-045
IGC Pharma, LLCIGC1PHASE2IGC-AD1-Active
Alnylam Pharmaceuticals, IncALNY2PHASE1ALN-5288, ALN-APP
Arrowhead Pharmaceuticals, Inc.ARWR1PHASE1ARO-MAPT-
Denali Therapeutics Inc.DNLI1PHASE1DNL628
AC Immune SAACIU2PHASE1ACI-24.060 at Dose A in Study Part 1a, ACI-24.060 at Dose B in Study Part 1a, ACI-24.060 at Dose C in Study Part 1a, ACI-24.060 with an additional adjuvant at Dose D in Study Part 1b, ACI-24.060 at Dose A in Study Part 2
Alzamend Neuro, Inc.ALZN1PHASE1ALZN002 .
Voyager Therapeutics, Inc.VYGR1PHASE1VY7523
Unlock Competitive Intelligence